The purpose of this study is to evaluate the long-term safety of teplizumab, in participants who previously completed the PROTECT study, for an additional 42 months (approximately 3.5 years) of follow-up.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
Nina Jain
Pediatrics - Children's Research Institute
Clinical or Medical
Observational
Diabetes
22-1426
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
